Latest News Feed
Successful loading of CBD material accelerates the path to revenue.
Exousia Pro is in a unique position, as only 11% of ODAs are awarded at the preclinical stage.
Focused on Protecting Shareholder Value and Advancing Core Business
Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately $50,000 in monthly revenue.
Exousia Pro aims to develop three new subdivisions and launch new products during the 4th quarter.
The market for our new products is currently valued at $8.7 billion, projected to grow to $18.5 billion over the next decade.
Dr. Marvin S. Hausman, MD, will be Chairman of the Scientific Advisory Board.
Dr. Marvin Hausman is joining Exousia Pro as a Consultant and will host a weekly series.
- Rigorous humanized mouse model enhances credibility and translatability of results
- Key preclinical data to support FDA Orphan Drug Application
- In vitro success signals potential for exosome-based therapy breakthrough
A published paper shows NANOG Expression was almost 100% effective at eradicating tumor cells
Exousia Pro has a 60% margin built-in on each order of exosomes